Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | June 24, 2026 | June 26, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | EVP, Chief Financial Officer | August 23, 2021 | August 25, 2021 |
| ViewRay, Inc.VRAY · Entity 111118 | Chief Financial Officer | March 01, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,392 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 4,392 · Balance 4,392 F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
HAEMONETICS CORP
Report date August 23, 2021 · Filed August 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,291 |
Last balance in matching sequence
After 2021-08-23 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-08-23 · Exercise / conversion · Acquired 11,232 · Balance 41,523 F3: This number includes unvested RSUs previously reported. Row 2 · 2021-08-23 · Exercise / conversion · Acquired 11,435 · Balance 52,958 F3: This number includes unvested RSUs previously reported. Row 3 · 2021-08-23 · Sale · Disposed 22,667 · Balance 30,291 F1: Transaction pursuant to an existing 10b5-1 trading plan. F2: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $60.06 to $60.88, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: This number includes unvested RSUs previously reported. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.21 · Expires 2023-10-25 | Direct | 0 |
Reported balance
After 2021-08-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-23 · Exercise / conversion · Disposed 11,232 · Balance 0 F1: Transaction pursuant to an existing 10b5-1 trading plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.64 · Expires 2024-06-06 | Direct | 0 |
Reported balance
After 2021-08-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-23 · Exercise / conversion · Disposed 11,435 · Balance 0 F1: Transaction pursuant to an existing 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to an existing 10b5-1 trading plan.
F2: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $60.06 to $60.88, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: This number includes unvested RSUs previously reported.
ViewRay, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 356,318 |
Reported balance
After 2023-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 103,686 · Balance 356,318 F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. A total of one-third of the shares subject to this grant become vested on each of the first three anniversaries of March 1, 2023, subject to the Reporting Person remaining a service provider through each such vesting date. F2: Includes 356,318 shares granted as RSUs. As of the transaction date, zero RSUs have vested. |
| Performance UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 103,686 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 103,686 · Balance 103,686 F3: These performance share awards were issued at a 100% target and have a 3-year vest period and will vest in all or in part upon achievement of performance metrics. Any awards that have not been vested and released at the end of the 3-year period will be cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. A total of one-third of the shares subject to this grant become vested on each of the first three anniversaries of March 1, 2023, subject to the Reporting Person remaining a service provider through each such vesting date.
F2: Includes 356,318 shares granted as RSUs. As of the transaction date, zero RSUs have vested.
F3: These performance share awards were issued at a 100% target and have a 3-year vest period and will vest in all or in part upon achievement of performance metrics. Any awards that have not been vested and released at the end of the 3-year period will be cancelled.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,413 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 66,943 · Balance 67,413 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 67,413 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001682069-26-000002 · wk-form4_1782507192.xml · derivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,392 Underlying: Common Stock · 4,392 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 20:35 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000076 · wk-form4_1782246910.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 20:35 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000076 · wk-form4_1782246910.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 3,591 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0000805928-25-000136 · wk-form4_1763069511.xml · derivative · entry 6 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,591 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This grant vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 3,591 | $24.02 | $86,248.64 |
DisclosureSEC source: 0000805928-25-000136 · wk-form4_1763069511.xml · nonDerivative · entry 4 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F2 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.13 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,591 | $8.14 | $29,230.74 |
DisclosureSEC source: 0000805928-25-000136 · wk-form4_1763069511.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 19,227 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0000805928-25-000136 · wk-form4_1763069511.xml · derivative · entry 5 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,591 Underlying: Common Stock · 19,227 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This grant vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 19,227 | $24.01 | $461,640.27 |
DisclosureSEC source: 0000805928-25-000136 · wk-form4_1763069511.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.10 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 19,227 | $8.14 | $156,507.78 |
DisclosureSEC source: 0000805928-25-000136 · wk-form4_1763069511.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 21:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 5,347 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0000805928-25-000134 · wk-form4_1762552351.xml · derivative · entry 6 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,818 Underlying: Common Stock · 5,347 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This grant vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 21:52 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 5,347 | $24.01 | $128,370.78 |
DisclosureSEC source: 0000805928-25-000134 · wk-form4_1762552351.xml · nonDerivative · entry 4 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F2 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.06 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 21:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,347 | $8.14 | $43,524.58 |
DisclosureSEC source: 0000805928-25-000134 · wk-form4_1762552351.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 11,431 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0000805928-25-000134 · wk-form4_1762552351.xml · derivative · entry 5 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,165 Underlying: Common Stock · 11,431 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This grant vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:52 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 11,431 | $24.05 | $274,892.69 |
DisclosureSEC source: 0000805928-25-000134 · wk-form4_1762552351.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.25 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,431 | $8.14 | $93,048.34 |
DisclosureSEC source: 0000805928-25-000134 · wk-form4_1762552351.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 18,248 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · derivative · entry 9 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,248 shares Expires 2034-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This grant vested on the first anniversary of the date of the grant, June 6, 2024. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 18,248 | $23.00 | $419,704.00 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · nonDerivative · entry 6 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F2 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 18,248 | $7.04 | $128,465.92 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · nonDerivative · entry 5 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 19,799 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · derivative · entry 8 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,596 Underlying: Common Stock · 19,799 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This grant vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to buy) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · derivative · entry 7 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This grant vested on the first anniversary of the date of the grant, September 1, 2023. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 19,799 | $22.00 | $435,578.00 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · nonDerivative · entry 4 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F2 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 19,799 | $8.14 | $161,163.86 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 20,436 | $19.15 | $391,435.23 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.50 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 20,436 | $6.30 | $128,746.80 |
DisclosureSEC source: 0000805928-25-000132 · wk-form4_1761941351.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,457 | $18.02 | $26,252.23 |
DisclosureSEC source: 0000805928-25-000125 · wk-form4_1761336538.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.045 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:18 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 736 | $18.00 | $13,248.74 |
DisclosureSEC source: 0000805928-25-000122 · wk-form4_1759871884.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,557 F1 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.01 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 6, 2025 20:54 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 14,571 | $18.21 | $265,282.54 |
DisclosureSEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 4 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,293 F4 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.60 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 6, 2025 20:54 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 7,600 | $18.21 | $138,367.12 |
DisclosureSEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 0 F3 · price: The sale is from the Elizabeth J. Burke 2024 Irrevocable Trust, of which William P. Burke is a stakeholder and a Trustee. F4 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.60 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:54 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 7,620 | $18.01 | $137,200.39 |
DisclosureSEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,864 F2 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.02 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:54 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 2,400 | $18.01 | $43,224.00 |
DisclosureSEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 7,600 F1 · price: The sale from the Elizabeth J. Burke 2024 Irrevocable Trust, of which William P. Burke is a stakeholder and a Trustee, reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.04 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 19, 2025 Filed Jun 20, 2025 20:08 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000098 · wk-form4_1750450115.xml · derivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:25 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 4,073 | $10.61 | $43,214.53 |
DisclosureSEC source: 0000805928-25-000083 · wk-form4_1749673506.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,484 F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000118 · wk-form4_1725496885.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000118 · wk-form4_1725496885.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:22 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 18,248 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0000805928-24-000101 · wk-form4_1718058141.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,248 Underlying: Common Stock · 18,248 shares Expires 2034-06-06 F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:22 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 10,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000805928-24-000101 · wk-form4_1718058141.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,653 F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 16:47 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerCommon Stock | 67,413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016375 · form4-12132023_091247.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · security: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4 · price: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 16:47 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | OtherCommon Stock | 66,943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016375 · form4-12132023_091247.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,413 F1 · shares: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F1 · price: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2 · price: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:33 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000120 · wf-form4_169408279774405.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:33 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000120 · wf-form4_169408279774405.xml · derivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 6,000 | $6.31 | $37,860.00 |
DisclosureSEC source: 0000805928-23-000106 · wf-form4_169299457138172.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F2 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $6.28 to $6.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:16 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 10,000 | $6.56 | $65,600.00 |
DisclosureSEC source: 0000805928-23-000106 · wf-form4_169299457138172.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 10,000 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in several transactions at prices ranging from $6.54 to $6.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 16:27 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 54,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009222 · form4-06052023_080618.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,356 F1 · shares: The RSUs shall vest upon the earlier of (i) the next annual meeting of the stockholders of the Company or (ii) June 1, 2024. Read SEC document |
| March 10, 2023 Filed Mar 30, 2023 16:57 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | PurchaseCommon Stock | 31,250 | $1.60 | $50,000.00 |
DisclosureSEC source: 0001415889-23-005631 · form4-03302023_080308.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,155 Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:24 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantPerformance Units · Derivative | 103,686 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-006348 · wf-form4_167788223829609.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,686 Underlying: Common Stock · 103,686 shares Expires not disclosed F3 · derivative.exercise_date: These performance share awards were issued at a 100% target and have a 3-year vest period and will vest in all or in part upon achievement of performance metrics. Any awards that have not been vested and released at the end of the 3-year period will be cancelled. F3 · derivative.expiration_date: These performance share awards were issued at a 100% target and have a 3-year vest period and will vest in all or in part upon achievement of performance metrics. Any awards that have not been vested and released at the end of the 3-year period will be cancelled. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:24 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 103,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-006348 · wf-form4_167788223829609.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,318 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. A total of one-third of the shares subject to this grant become vested on each of the first three anniversaries of March 1, 2023, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · balance_after: Includes 356,318 shares granted as RSUs. As of the transaction date, zero RSUs have vested. Read SEC document |
| January 16, 2023 Filed Jan 17, 2023 16:15 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 252,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-001109 · wf-form4_167399010531321.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,632 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. A total of one-third of the shares subject to this grant become vested on each of the first three anniversaries of January 16, 2023, subject to the Reporting Person remaining a service provider through each such vesting date. Read SEC document |
| August 10, 2022 Filed Aug 16, 2022 09:36 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 12,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008656 · form4-08162022_060820.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,905 F1 · shares: Restricted Stock Units ("RSUs") that will fully vest on the earlier of the next annual meeting or one year from the date of the grant. Read SEC document |
| July 19, 2022 Filed Jul 19, 2022 20:02 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 59,395 | $8.14 Strike: $8.14 | $483,475.30 |
DisclosureSEC source: 0000805928-22-000079 · wf-form4_165826091626398.xml · derivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Stock Option (right to purchase) · 59,395 shares Expires 2023-07-11 F1 · derivative.exercise_date: 1. Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on July 11, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:46 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 31,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000267 · edgar.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,117 F2 · shares: RSUs that vest as follows: 10,571 vest on January 3, 2023; the remaining 21,142 vest thereafter over eight quarters with first five quarters vesting 2,643 each quarter and the final three quarters vesting 2,642 each quarter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.